Chardan Capital Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30

Benzinga · 05/08 11:17
Chardan Capital analyst Rudy Li initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $30.